Study Stopped
Reagants to test mediators couldnot be procured
Study of Mediators of Post Hepatectomy Liver Regeneration
Prospective Non-randomized Trial to Study Expression of Mediators of Post Hepatectomy Liver Regeneration(PHLR) and Compare With a Non-hepatectomy Group: a Pilot Study
1 other identifier
observational
10
1 country
1
Brief Summary
Prospective non-randomized trial to study expression of mediators of post hepatectomy liver regeneration (PHLR) and compare with a non-hepatectomy group: a pilot study Background : Experimental studies using post hepatectomy animal models have been used to study the mechanism of liver regeneration. Hepatectomy for various diseases and living donor liver transplant provide a good human model to study in vivo mechanism of liver regeneration. These studies are necessary for the clinical application of the knowledge obtained by animal experiments and will guide further research to develop new modalities for the management of hepatic failure, cirrhosis and cancer. Null hypothesis: Expression of mediators of post hepatectomy liver regeneration (PHLR) is not different between hepatectomy (study group) and non hepatectomy group (control group). Aim: To study the mechanism of post hepatectomy liver regeneration(PHLR) and compare expression of mediators of PHLR between hepatectomy (study group) and a non-hepatectomy group (control group). Patient and method: This prospective non randomized trail will be conducted on two group of patients- hepatectomy (Study) group and non-hepatectomy (control) group and minimum 10 consecutive adult (18 year or more) patients will be recruited in each group according to inclusion and exclusion criteria given below. Informed consent will be obtained from the patients in both the groups. Peripheral (from a forearm vein) venous blood (6 ml) will be collected a day before surgery and at different intervals after surgery (day 1, day 3,7, 2 weeks, 6 weeks and 6 months). A small branch of portal vein will be cannulated a 20 gauge intravenous catheter for measurement of portal pressure and collection of portal venous blood (6 ml) at the start (after entry inside the abdomen) and at the end (before closure of the abdomen). Patients in hepatectomy (study) group will undergo trucut (needle) biopsy from the remnant liver. Mediators of liver regeneration will be measured by standard methods in blood samples from both groups. The liver tissue from study group will also be analysed for factors related to initiation of PHLR.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Mar 2013
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2013
CompletedFirst Submitted
Initial submission to the registry
February 21, 2014
CompletedFirst Posted
Study publicly available on registry
March 4, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2021
CompletedAugust 6, 2021
July 1, 2021
8.3 years
February 21, 2014
July 30, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum level (in picogram/ml) of IL-1, IL-6, TNF alfa, TNF beta,HGF, GH, Insulin, Glucagon
change in serum level of mediators from baseline (before surgery)
Before surgery and day 1, 3,7,14,42 and 180 after surgery
Study Arms (2)
study (hepatectomy) group
patients undergoing hepatectomy for malignant neoplasm
control (non hepatectomy) group
patients undergoing intestinal resections (not incluiding hepatectomy) for malignant neoplasm
Eligibility Criteria
liver regeneration in patient with hepatectomy
You may qualify if:
- adult (18 year or more)
- hepatectomy for malignant neoplasm (study group)
- other GI resections for malignant G I tract tumors
- willing to participate
You may not qualify if:
- less than 18 years in age
- not willing to participate
- immunosuppression
- chronic hepatitis
- cirrhosis
- portal hypertension
- pregenancy
- oral contraceptives
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
G B Pant Hospital
New Delhi, National Capital Territory of Delhi, 110002, India
Study Officials
- PRINCIPAL INVESTIGATOR
hirdaya h nag, ms
gobind ballabh pant hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor in G I Surgery
Study Record Dates
First Submitted
February 21, 2014
First Posted
March 4, 2014
Study Start
March 1, 2013
Primary Completion
July 1, 2021
Study Completion
July 1, 2021
Last Updated
August 6, 2021
Record last verified: 2021-07